The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Open accessAbstract
HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This approach has shown efficacy in colon cancer and NSCLC patients with mutant KRAS G12D and HLA-C*08:02 expression [88].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tumors with mutant KRAS can express neoantigen fragments containing the oncogenic driver mutation on the major histocompatibility complex [88,89].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
In the citing paper
“CD8+ TILs and TCRs in CD4+ T cells have been found to specifically recognize KRAS-related mutations, which can be further used to engineer T cells.604,605”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [604]
In the citing paper
“As noted above, peptides derived from KRASG12 variants193,194, and also from KRASQ61H/L/R (ref.198), have been demonstrated to be presented on the surface of malignant cells by various MHC I (HLA-A) molecules.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“ACT with these specific TILs resulted in regression of all seven pulmonary metastases in a patient with KRASG12D-mutant CRC from whom they had been isolated193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Notably, loss of MHC was identified as an immune-evasion mechanism in a tumour that progressed 9 months after TIL infusion193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Endogenous immune responses against KRAS-mutant cancer cells were first described in 2016 by Tran et al.193, who identified CD8+ TILs with T cell receptors (TCRs) that recognize MHC I (HLA-C*08:02)-presented peptide neoepitopes derived from KRASG12D.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Using CD8+ T cells that were reactive to KRASG12D mutant, a patient with CRC experienced prolonged partial response [64].”
From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [64]
In the citing paper
“It was found that CD8+ T cells, possessing HLA-C08:02-restricted T-cell receptors, specifically recognize the mutant KRASG12D.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Following the intravenous administration of expanding TCRs in an ex vivo environment, a complete response was observed in lung lesions, resulting in prolonged PFS.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“A recent publication presented the relationship between the KRASG12D mutation and TCRs in a patient diagnosed with metastatic mCRC with lung metastasis [106].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Despite the rarity of HLA-C*08:02, this study demonstrated the promise of T-cell–based immunotherapy for targeting KRASG12D and HLA-C*08:02.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“Tran and colleagues described a case of a patient with metastatic colorectal cancer treated with autologous T cells specific for mutant KRASG12D, which was restricted to the major histocompatibility complex class I allele HLA-C*08:02 (44).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“The anti-tumor activity of ICB has been shown to depend on CD8+ T cell, HLA class I–dependent immune activity (34–36).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208
Self-citationCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625
Self-citationAllele-specific copy number analysis of tumors
Loo, P. V., Nord, S., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,192
Cited by
Sorted by citations
Items 801–900 of 1,002
Li, D., Chen, C., Li, J., Yue, J., Ding, Y., Wang, H., Liang, Z., Zhang, L., Qiu, S., Liu, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39225-7 · Cited by 13
Immune engineering: From systems immunology to engineering immunity
Jiang, N. J. (2017) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2017.03.002 · Cited by 14
Rao, M., Ligeiro, D., & Maeurer, M. J. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000575 · Cited by 13
Precision Medicine-Enabled Cancer Immunotherapy
Lee, J. K., & Priceman, S. J. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_7 · Cited by 13
NextGen cell-based immunotherapies in cancer and other immune disorders
Azimi, C. S., Tang, Q., Roybal, K. T., & Bluestone, J. A. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.03.007 · Cited by 13
Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application
Xie, N., Shen, G., Huang, C., & Zhu, H. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003708 · Cited by 13
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors
Bandlamudi, C., Muldoon, D. M., de Bruijn, I., Zhang, M., Gormally, M. V., Harrold, E. C., Nandakumar, S., Smith, S. A., Jeng, M. Y., Woods, S., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.03.003 · Cited by 13
Erickson, T. A., Shih, Y.-P., Fass, J. N., Jang, M., & Tran, E. (2022) · Thyroid · doi:10.1089/thy.2022.0020 · Cited by 12
Self-citationNeoantigens: The Novel Precision Cancer Immunotherapy
Zhang, T., Kurban, E., & Wang, Z. (2023) · Biologics · doi:10.3390/biologics3040017 · Cited by 12
Cell-Based Therapies in GI Cancers: Current Landscape and Future Directions
Nakayama, I., & Shitara, K. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-471716 · Cited by 12
Individualized Neoantigen-Directed Melanoma Therapy
Khaddour, K., & Buchbinder, E. I. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00920-4 · Cited by 13
Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients
Balan, S., Finnigan, J. P., & Bhardwaj, N. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000251 · Cited by 12
Nature of tumour rejection antigens in ovarian cancer
Want, M. Y., Lugade, A. A., Battaglia, S., & Odunsi, K. O. (2018) · Immunology · doi:10.1111/imm.12951 · Cited by 13
Zhang, C., Huang, H., Miao, Y., Xiong, H., & Lu, Z. (2018) · The Journal of Pathology · doi:10.1002/path.5142 · Cited by 12
Identification of Antigenic Targets
Gerber, H., Sibener, L. V., Lee, L. J., & Gee, M. H. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.002 · Cited by 12
The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients
Arnaud, M., Bobisse, S., Chiffelle, J., & Harari, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701636 · Cited by 13
Schoenberg, M. B., Li, X., Li, X., Han, Y., Börner, N., Koch, D. T., Guba, M. O., Werner, J. M., & Bazhin, A. V. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108220 · Cited by 12
Tokatlian, T., Asuelime, G. E., Naradikian, M. S., Mock, J., Daris, M. E., Martin, A. D., Warshaviak, D. T., Kamb, A., & Hamburger, A. E. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0165 · Cited by 12
Neoantigens and NK Cells: “Trick or Treat” the Cancers?
Lv, D., Khawar, M. B., Liang, Z., Gao, Y. M., & Sun, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931862 · Cited by 12
Adoptive cell transfer therapy for melanoma
Inozume, T. (2022) · Experimental Dermatology · doi:10.1111/exd.14707 · Cited by 12
Clinical Trials of Cellular Therapies in Solid Tumors
Secondino, S., Canino, C., Alaimo, D., Muzzana, M., Galli, G., Borgetto, S., Basso, S., Bagnarino, J., Pulvirenti, C., Comoli, P., et al. (2023) · Cancers · doi:10.3390/cancers15143667 · Cited by 12
Strategies to overcome low MHC-I expression in paediatric and adult tumours
Guillaume, J., Perzolli, A., & Boes, M. L. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad028 · Cited by 12
Neoantigens – the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders
Sabdia, M. B., Patch, A., Tsang, H., & Gandhi, M. K. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100969 · Cited by 14
Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies
Daniyan, A. F., & Brentjens, R. J. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.49 · Cited by 12
Inactivation of DNA repair—prospects for boosting cancer immune surveillance
Truini, A., Germano, G., & Bardelli, A. (2018) · Genome Medicine · doi:10.1186/s13073-018-0603-9 · Cited by 12
KRAS, a New Target for Precision Medicine in Colorectal Cancer?
Boilève, A., Smolenschi, C., Lambert, A., Boige, V., Delaye, M., Camilleri, G. M., Tarabay, A., Valéry, M., Fuerea, A., Pudlarz, T., et al. (2024) · Cancers · doi:10.3390/cancers16203455 · Cited by 11
Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer
Morris, L. G. T. (2023) · The Laryngoscope · doi:10.1002/lary.30761 · Cited by 11
Lian, Y., Zeng, S., Wen, S., Zhao, X., Fang, C., & Zeng, N. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231189399 · Cited by 12
Yao, P., Gao, M., Hu, W., Wang, J., Wang, Y., Wang, Q., & Ji, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107209 · Cited by 11
Introducing Neoadjuvant Immunotherapy for Colorectal Cancer
Orhan, A., Justesen, T. F., Raskov, H., Qvortrup, C., & Gögenür, I. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006443 · Cited by 13
Xu, X., Guo, S., Gu, H., Cha, Z., Shi, X., Yin, X., Wang, H., Gao, S., Li, B., Zhu, L., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.181873 · Cited by 11
Self-citationShoushtari, A. N., & Powell, D. J. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.11.017 · Cited by 11
Nsingwane, Z., Candy, G. P., Devar, J. W., Omoshoro–Jones, J., Smith, M., & Nweke, E. E. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05648-4 · Cited by 13
HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival
Dimou, A., Grewe, P., Sidney, J., Sette, A., Norman, P. J., & Doebele, R. C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.08.023 · Cited by 11
Stringhini, M., Spadafora, I., Catalano, M., Mock, J., Probst, P., Spörri, R., & Neri, D. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02912-9 · Cited by 11
Katagiri, W., Yokomizo, S., Ishizuka, T., Yamashita, K., Kopp, T., Roeßing, M., Satô, A., Iwasaki, T., Sato, H., Fukuda, T., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202200033r · Cited by 11
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges
Song, Z., Lu, L., Gao, Z., Zhou, Q., Wang, Z., Sun, L., & Zhou, Y. (2022) · Future Oncology · doi:10.2217/fon-2021-1549 · Cited by 13
Millar, D. G., Yang, S. Y. C., Sayad, A., Zhao, Q., Nguyen, L. T., Warner, K., Sangster, A. G., Nakatsugawa, M., Murata, K., Wang, B. X., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03413-7 · Cited by 12
Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD
Chen, M., Zhang, X., Ming, Z., Lingyu, Feng, X., Han, Z., & An, H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05103-z · Cited by 11
Tumor neoantigens and tumor immunotherapies
Jiani, W., Qin, T., & Ma, J. (2024) · Aging Medicine · doi:10.1002/agm2.12295 · Cited by 12
Engineering Platforms for T Cell Modulation
Hickey, J. W., Kosmides, A. K., & Schneck, J. P. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.003 · Cited by 11
Cancer Exome-Based Identification of Tumor Neo-Antigens Using Mass Spectrometry
Kalaora, S., & Samuels, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8885-3_14 · Cited by 11
Gene editing: Towards the third generation of adoptive T-cell transfer therapies
Puig-Saus, C., & Ribas, A. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.06.001 · Cited by 12
Qian, F., & Han, B. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001124 · Cited by 11
IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells
Kehl, N., Kilian, M., Michel, J., Wagner, T. R., Uhrig, S., Brobeil, A., Sester, L. S., Blobner, S., Steiger, S., Hundemer, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005815 · Cited by 12
Combating NRAS Mutant Melanoma: From Bench to Bedside
Echevarría-Vargas, I. M., & Villanueva, J. (2017) · Melanoma Management · doi:10.2217/mmt-2017-0023 · Cited by 11
Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025) · Medicina · doi:10.3390/medicina61071202 · Cited by 10
Wang, C., Chen, J., Li, J., Xu, Z., Huang, L., Zhao, Q., Chen, L., Liang, X., Hu, H., Li, G., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci172092 · Cited by 11
Recent Advancements in Cell-Based Therapies in Melanoma
Nassief, G., Anaeme, A., Moussa, K., Mansour, A., & Ansstas, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189848 · Cited by 10
MicroEpitope: an atlas of immune epitopes derived from cancer microbiomes
Li, D., Cai, Y., Liu, K., Lv, D., Zeng, M., Wen, L., Lv, C., Guo, J., Xu, K., Ding, N., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae877 · Cited by 10
Füchsl, F., Untch, J., Kavaka, V., Zuleger, G., Braun, S., Schwanzer, A., Jarosch, S., Vogelsang, C., Krätzig, N. D. A., Gosmann, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53911-0 · Cited by 11
Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates
Kim, J., Kim, H. S., Nam, M., & Chae, Y. K. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10274-2 · Cited by 12
Melanoma: Pathogenesis and Targeted Therapy
Fu, Y., Liu, J., Mo, Z., Wang, B., Deng, Y., & Jiang, Y. (2026) · MedComm · doi:10.1002/mco2.70566 · Cited by 11
T cell immunotherapy for solid tumors: limitations, progress, and future prospects
Wang, Y., Zhang, B., Wang, Y., Tan, Y., Hu, X., Che, X., & Feng, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1755751 · Cited by 11
Regulation of the Small GTPase Ras and Its Relevance to Human Disease
Kulhanek, K. R., Roose, J. P., & Rubio, I. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1190-6_2 · Cited by 10
Pandey, A. K., Iraqi, M., Toledo, E., Yassin, A. A., Podvalni, E., Naaz, S., Pandit, J. J., Martín, C. U., Saux, G. L., Porgador, A., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c01871 · Cited by 10
New insights into RAS in head and neck cancer
Jagadeeshan, S., Novoplansky, O., Cohen, O. M., Kurth, I., Heß, J., Rosenberg, A. J., Grandis, J. R., & Elkabets, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188963 · Cited by 11
Zemánek, T., Nová, Z., & Nicodemou, A. (2023) · Physiological Research · doi:10.33549/physiolres.935155 · Cited by 10
Amhis, N., Carignan, J., & Tai, L. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200825 · Cited by 10
Functional genomics: paving the way for more successful cancer immunotherapy
Ajina, R., Zamalin, D., & Weiner, L. M. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely017 · Cited by 11
Potential advantages of CD1-restricted T cell immunotherapy in cancer
Consonni, M., Dellabona, P., & Casorati, G. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.09.025 · Cited by 10
Solomon, B., Beavis, P. A., & Darcy, P. K. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281101 · Cited by 10
Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer
Gorgulho, C. M., Krishnamurthy, A., Lanzi, A., Galon, J., Housseau, F., Kaneno, R., & Lotze, M. T. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000357 · Cited by 12
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues
Yoo, S. H., Yun, J., Keam, B., Hong, S.-P., Ock, C.-Y., Koh, J., Kim, S., Jeon, Y. K., Jung, K. C., Kim, M., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02799-y · Cited by 10
Teo, M. Y. M., Ng, J. J. C., Fong, J. Y., Hwang, J. S., Song, A. A., Lim, R. L. H., & In, L. L. A. (2021) · PeerJ · doi:10.7717/peerj.11063 · Cited by 10
Tools to define the melanoma‐associated immunopeptidome
Bräunlein, E., & Krackhardt, A. M. (2017) · Immunology · doi:10.1111/imm.12803 · Cited by 10
Mohapatra, S. S., Batra, S. K., Bharadwaj, S. N., Bouvet, M., Cosman, B. C., Goel, A., Jogunoori, W. S., Kelley, M. J., Mishra, B., Mishra, B., et al. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5000-0 · Cited by 10
Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation
Bai, P., Zhou, Q., Wei, P., Bai, H., Chan, S. K., Kappler, J. W., Marrack, P., & Yin, L. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1888-1 · Cited by 10
Mishto, M., Rodriguez-Hernandez, G., Neefjes, J., Urlaub, H., & Liepe, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679836 · Cited by 10
Future of Surgery: Technology Enhanced Surgical Training: Report of the FOS:TEST Commission
Adebayo, O., Aldoori, J., Allum, W., Aruparayil, N., Badran, A., Beatty, J. W., Bhatia, S., Bolton, W., Giwa, L., Burke, J., et al. (2022) · doi:10.1308/fos2.2022 · Cited by 11
Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Chang, J.-F., Landmann, J. H., Chang, T.-C., Selli, M. E., Tenzin, Y., Warrington, J. M., Ritchey, J., Hsu, Y.-S., Slade, M., Gupta, D. K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1393 · Cited by 10
Tumor Antigens beyond the Human Exome
Emilius, L., Bremm, F., Binder, A. K., Schaft, N., & Dörrie, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094673 · Cited by 9
Luo, J., Yi, T., Wang, Y., Wei, S., Gao, Z., Wang, J., & Li, Y. (2025) · Scientific Reports · doi:10.1038/s41598-024-82400-z · Cited by 9
Salzler, R. R., DiLillo, D. J., Saotome, K., Bray, K., Mohrs, K., Hwang, H., Cygan, K. J., Shah, D., Rye-Weller, A., Kundu, K., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ado9371 · Cited by 9
Conn, B. P., Dietze, J. L., Yee, C. J., Hallisey, M., Ortiz-Caraveo, I., van Buuren, M. M., Gaynor, R. B., Foley, K. C., Choi, J., & Juneja, V. R. (2025) · Cell Reports Methods · doi:10.1016/j.crmeth.2025.101049 · Cited by 9
Tian, H., Li, G., Chiu, C. K. C., Li, E. L., Chen, Y., Zhu, T., Hu, M., Wang, Y., Wen, S., Li, J., et al. (2025) · Cell Insight · doi:10.1016/j.cellin.2025.100251 · Cited by 9
Xu, X., Gu, H., Cha, Z., Zhang, B., Yuan, S., Ding, X., Gao, L., Gao, S., Wu, X., Gu, L., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.012 · Cited by 9
Self-citationEmerging Treatment Strategies in Pancreatic Cancer
Trunk, A. D., Miotke, L. K., Nevala-Plagemann, C., Verdaguer, H., Macarulla, T. M., & Garrido‐Laguna, I. (2021) · Pancreas · doi:10.1097/mpa.0000000000001845 · Cited by 11
Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer
Cho, S. H., Yoon, S., Lee, K. H., Kim, S.-W., & Kim, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-99197-w · Cited by 9
Wu, D., Liang, S., Guo, H., Zhang, S., Yang, G., Yuan, Y., & Liu, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.790093 · Cited by 9
Xu, R., Wang, Q., Zhu, J., Bei, Y., Chu, Y., Sun, Z., Du, S., Zhou, S., Ding, N., Meng, F., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10585 · Cited by 9
Regional and intratumoral adoptive T-cell therapy
Olivera, I., Etxeberría, I., Luri‐Rey, C., Molero-Glez, P., & Melero, I. (2024) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2024.100715 · Cited by 9
Chee, J., Wilson, C., Buzzai, A. C., Wylie, B., Forbes, C. A., Booth, M. W., Principe, N., Foley, B. A., Cruickshank, M. N., & Waithman, J. C. (2019) · Epigenetics · doi:10.1080/15592294.2019.1656156 · Cited by 9
Lee, H. J., Kim, Y., Kim, Y., Park, H. S., Seo, J.-H., Lee, H., Gong, G., & Lee, H. J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02633-5 · Cited by 9
D’Ippolito, E., Wagner, K. I., & Busch, D. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218324 · Cited by 10
Tackling HLA Deficiencies Head on with Oncolytic Viruses
Fisher, K. D., Hazini, A., & Seymour, L. W. (2021) · Cancers · doi:10.3390/cancers13040719 · Cited by 10
The Adaptive Immune Landscape of the Colorectal Adenoma–Carcinoma Sequence
de Freitas, J. A. T., Gullo, I., Garcia, D., Miranda, S., Spaans, L. N., Pinho, L., Reis, J. P., de Sousa, F. S., Baptista, M., Resende, C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189791 · Cited by 9
Immunotherapy of Cancer: Targeting Cancer During Active Disease or During Dormancy?
Shah, S. A., Zarei, M., Manjili, S. H., Guruli, G., Wang, X., & Manjili, M. H. (2017) · Immunotherapy · doi:10.2217/imt-2017-0044 · Cited by 9
Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer
Yin, Q., Tang, J., & Zhu, X. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely018 · Cited by 9
Immunological-based approaches for cancer therapy
Barros, L. R. C., Pretti, M. A. M., Chicaybam, L., Abdo, L. D. M., Boroni, M., & Bonamino, M. (2018) · Clinics · doi:10.6061/clinics/2018/e429s · Cited by 9
ADOPTIVE CELL THERAPY: CURRENT ADVANCES
Shamova, T. V., Sitkovskaya, A. О., Vashchenko, L. N., & Kechedzhieva, E. E. (2020) · South Russian Journal of Cancer · doi:10.37748/2687-0533-2020-1-1-4 · Cited by 9
Zhou, Q., Chen, D., Zhang, J., Xiang, J.-F., Zhang, T., Wang, H., & Zhang, Y. (2022) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000109 · Cited by 9
Sim, M. J. W., Hanada, K., Stotz, Z., Yu, Z., Lu, J., Brennan, P., Quastel, M. N., Gillespie, G. M. A., Long, E. O., Yang, J. C.-H., et al. (2024) · European Journal of Immunology · doi:10.1002/eji.202451079 · Cited by 8
Maravelia, P., Yao, H., Cai, C., Silva, D. N., Fransson, J., Nilsson, O. B., Lu, Y., Micke, P., Botling, J., Gatto, F., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334148 · Cited by 8
Self-citationLennerz, V., Doppler, C., Fatho, M., Dröge, A., Schaper, S., Gennermann, K., Genzel, N., Plaßmann, S., Weismann, D., Lukowski, S. W., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1509855 · Cited by 8
Adoptive immune cell therapy for colorectal cancer
Liu, C., Liu, N., Zhang, T., & Tu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1557906 · Cited by 8
Xiao, L., Duan, R., Liu, W., Zhang, C., Ma, X., Xian, M., Wang, Q., Guo, Q., Xiong, W., Pan, S., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00935-0 · Cited by 8
Self-citationOseni, S. O., Wang, Y., & Hwu, P. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.013 · Cited by 8
Braun, M. W., Abdelhakim, H., Li, M., Hyter, S. D., Pessetto, Z. Y., Koestler, D. C., Pathak, H. B., Dunavin, N., & Godwin, A. K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000706 · Cited by 8
Soluble Expression of Fc-Fused T Cell Receptors Allows Yielding Novel Bispecific T Cell Engagers
Zhao, W., Shen, Y., Liu, W., Li, Y., Jin, S., Xu, Y., Pan, L., Zhou, Z. M., & Chen, S. (2021) · Biomedicines · doi:10.3390/biomedicines9070790 · Cited by 8
Metadata
- Authors
- Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., Kriley, I. R., & Rosenberg, S. A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-08
- Volume
- 375
- Issue
- 23
- Pages
- 2255-2262
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5178827
- OpenAlex
- W2559953355
- Cited by
- 1,368
- References
- 27
- Citations by year
- 2026: 96 · 2025: 132 · 2024: 129 · 2023: 162 · 2022: 162 · 2021: 183 · 2020: 149 · 2019: 134 · 2018: 118 · 2017: 98 · 2016: 3
- FWCI
- 71.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC010984)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- tumor-infiltrating lymphocytes, mutant KRAS, KRAS G12D, CD8+ T cells, tumor immune evasion, MHC class I loss, cancer immunotherapy
- MeSH terms
- Female, Flow Cytometry, Humans, Lung, Lung Neoplasms, Middle Aged, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), CD8-Positive T-Lymphocytes, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
